Asia Pacific Age Related Macular Degeneration (AMD) Market Size, Share & Industry Trends Analysis Report By Drug Type (Aflibercept, Ranibizumab and Others), By Disease Type (Wet and Dry), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Age Related Macular Degeneration (AMD) Market should witness market growth of 6.4% CAGR during the forecast period (2023-2030).

The advancement of the market is aided by the increased incentives to pay for medications for age-related macular degeneration (AMD). A rise in the prevalence of eye problems is driving the \ market. A growing market trend, like the development of gene therapy for age-related macular degeneration, will lead to an increase in medical therapy for age-related macular degeneration.

Only a few medications, mostly anti-VEGFs, are now authorized to treat age-related macular degeneration. Frequent and unpleasant intraocular injections are required when using anti-VEGF drugs, which adds to the burden and results in non-adherence to therapy. Companies are working on longer-acting anti-VEGFs and vitreous implants that enable sustained medication delivery to overcome this obstacle. It is anticipated that the introduction of long-acting anti-VEGF medications like Beovu and Vabysmo will stimulate market expansion during the following years.

According to the National Library of Medicine, 81 patients (81 eyes) with dry AMD were included in Japan's survey of the condition. The mean age of the 81 patients was 76.6 8.4 years (range, 54-94), and 56 (69.1%) of them were men. 24 patients (29.5%) had a history of smoking. In 25 eyes (30.9%), the decimal best corrected-visual acuity (BCVA) was equal to or greater than 0.7, whereas, in 17 eyes (21.0%), it was less than 0.1. Of the 81 patients, dry AMD was found in 26 eyes (32.1%), neovascular AMD in 16 eyes (19.8%), and intermediate AMD in 18 eyes (22.2%) of those with the condition. The market is projected to expand as more individuals with AMD live in regional nations.

The China market dominated the Asia Pacific Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $849.1 million by 2030. The Japan market is registering a CAGR of 5.6% during (2023-2030). Additionally, The India market would showcase a CAGR of 6.9% during (2023-2030).

Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.

Scope of the Study

By Drug Type

• Aflibercept
• Ranibizumab
• Others

By Disease Type

• Wet
• Dry

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Biogen, Inc.
• Bayer AG
• Apellis Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.
• F.Hoffmann-La Roche Ltd.
• Ionis Pharmaceuticals, Inc.
• Novartis AG
• Sanofi S.A.
• Coherus Biosciences, Inc.
• Bausch Health Companies, Inc.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free